MEP13908A - 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations - Google Patents

6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations

Info

Publication number
MEP13908A
MEP13908A MEP-139/08A MEP13908A MEP13908A ME P13908 A MEP13908 A ME P13908A ME P13908 A MEP13908 A ME P13908A ME P13908 A MEP13908 A ME P13908A
Authority
ME
Montenegro
Prior art keywords
treatment
alkenyl
compounds
alkinyl
epoxy
Prior art date
Application number
MEP-139/08A
Other languages
Bosnian (bs)
English (en)
Inventor
Ulrich Klar
Wolfgang Schwede
Werner Skuballa
Bernd Buchmann
Jens Hoffmann
Rosemarie Lichtner
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19921086A external-priority patent/DE19921086A1/de
Priority claimed from DE19954228A external-priority patent/DE19954228A1/de
Priority claimed from DE10015836A external-priority patent/DE10015836A1/de
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of MEP13908A publication Critical patent/MEP13908A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MEP-139/08A 1999-04-30 2000-05-01 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations MEP13908A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19921086A DE19921086A1 (de) 1999-04-30 1999-04-30 6-Alkenyl- und 6-Alkinyl-Epothilon Derivate, Verfahren zu deren Herstellung sowie ihre Verwendung in pharmazeutischen Präparaten
DE19954228A DE19954228A1 (de) 1999-11-04 1999-11-04 6-Alkenyl-und 6-Alkinyl-Epothilon-Derivate, Verfahren zu deren Herstellung sowie ihre Verwendung in pharmazeutischen Präparaten
DE10015836A DE10015836A1 (de) 2000-03-27 2000-03-27 6-Alkenyl- und 6-Alkinyl-Epothilon-Derivate, Verfahren zu deren Herstellung sowie ihre Verwendung in pharmazeutischen Präparaten
PCT/IB2000/000657 WO2000066589A1 (en) 1999-04-30 2000-05-01 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations

Publications (1)

Publication Number Publication Date
MEP13908A true MEP13908A (en) 2010-06-10

Family

ID=27213767

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-139/08A MEP13908A (en) 1999-04-30 2000-05-01 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations

Country Status (33)

Country Link
EP (1) EP1173441B1 (et)
JP (2) JP4024003B2 (et)
KR (1) KR100721488B1 (et)
CN (1) CN100368415C (et)
AR (1) AR023792A1 (et)
AT (1) ATE440847T1 (et)
BG (1) BG65601B1 (et)
BR (1) BR0010190A (et)
CA (2) CA2651653C (et)
CY (1) CY1109768T1 (et)
CZ (1) CZ299653B6 (et)
DE (1) DE60042821D1 (et)
DK (1) DK1173441T3 (et)
EA (1) EA011502B1 (et)
EE (1) EE05292B1 (et)
ES (1) ES2331506T3 (et)
HK (1) HK1046681B (et)
HR (1) HRP20010892A2 (et)
HU (1) HUP0201010A3 (et)
IL (1) IL145938A0 (et)
ME (1) MEP13908A (et)
MX (1) MXPA01011039A (et)
NO (1) NO328149B1 (et)
NZ (1) NZ514989A (et)
PE (1) PE20010116A1 (et)
PL (1) PL210762B1 (et)
PT (1) PT1173441E (et)
RS (1) RS51023B (et)
SI (1) SI1173441T1 (et)
SK (1) SK286858B6 (et)
TW (2) TWI294292B (et)
WO (1) WO2000066589A1 (et)
ZA (1) ZA200109859B (et)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE261961T1 (de) 1995-11-17 2004-04-15 Biotechnolog Forschung Gmbh Epothilon-derivate, ihre herstellung und verwendung
DE59712968D1 (de) 1996-11-18 2008-10-30 Biotechnolog Forschung Gmbh Epothilone E und F
US6242469B1 (en) 1996-12-03 2001-06-05 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
US6498257B1 (en) 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
US6380395B1 (en) 1998-04-21 2002-04-30 Bristol-Myers Squibb Company 12, 13-cyclopropane epothilone derivatives
US6518421B1 (en) 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
US6593115B2 (en) 2000-03-24 2003-07-15 Bristol-Myers Squibb Co. Preparation of epothilone intermediates
DE10020899A1 (de) * 2000-04-20 2001-10-25 Schering Ag 9-Oxa-Epothilon-Derivate, Verfahren zu deren Herstellung sowie ihre Verwendung in pharmazeutischen Präparaten
UA75365C2 (en) * 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
WO2002058699A1 (en) 2001-01-25 2002-08-01 Bristol-Myers Squibb Company Pharmaceutical forms of epothilones for oral administration
EP1353667A1 (en) 2001-01-25 2003-10-22 Bristol-Myers Squibb Company Parenteral formulations containing epothilone analogs
EE05301B1 (et) 2001-01-25 2010-06-15 Bristol-Myers Squibb Company Meetod epotilooni analooge sisaldavate ravimvormide valmistamiseks ning nende kasutamine ravimi valmistamiseks
IL157128A0 (en) 2001-02-20 2004-02-08 Bristol Myers Squibb Co Pharmaceutical compositions containing epothilone derivatives
PL363362A1 (en) 2001-02-20 2004-11-15 Bristol-Myers Squibb Company Treatment of refractory tumors using epothilone derivatives
JP2004529904A (ja) 2001-03-14 2004-09-30 ブリストル−マイヤーズ　スクイブ　カンパニー 増殖性疾患の治療のためのエポシロン類似体および化学療法剤の組み合わせ
JP2004532888A (ja) 2001-06-01 2004-10-28 ブリストル−マイヤーズ　スクイブ　カンパニー エポチロン誘導体
EP1340498A1 (en) * 2002-03-01 2003-09-03 Schering Aktiengesellschaft Use of epothilones in the treatment of brain diseases associated with proliferative processes
AU2003218107A1 (en) 2002-03-12 2003-09-29 Bristol-Myers Squibb Company C12-cyano epothilone derivatives
DK1483251T3 (da) 2002-03-12 2010-04-12 Bristol Myers Squibb Co C3-cyano-epothilon-derivater
TW200403994A (en) 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
TW200400191A (en) 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
WO2003105828A1 (en) 2002-06-14 2003-12-24 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
BRPI0314133A8 (pt) 2002-09-23 2017-09-19 Bristol Myers Squibb Co Processo para isolamento de epotilona b, métodos para cultivo de microorganismo que produza epotilona a ou b e para purifiação de apotilona
DE10361794B3 (de) * 2003-12-31 2005-10-06 Schering Ag Optisch aktive heteroaromatische ß-Hydroxy-Ester und Verfahren zu deren Herstellung sowie deren Verwendung als Zwischenprodukte bei der Epothilon-Totalsynthese
EP1559447A1 (en) 2004-01-30 2005-08-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism
EP1640004A1 (en) * 2004-09-24 2006-03-29 Schering Aktiengesellschaft Use of epothilones in the treatment of bone metastases and bone tumors or cancers
US20060121511A1 (en) 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
EP1674098A1 (en) 2004-12-23 2006-06-28 Schering Aktiengesellschaft Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
CN100384419C (zh) * 2005-12-02 2008-04-30 菏泽睿鹰制药集团有限公司 一种埃坡霉素缓释植入组合物及应用
DE102007016046A1 (de) 2007-03-30 2008-10-23 Bayer Schering Pharma Aktiengesellschaft Verfahren zur Herstellung von Epothilonderivaten durch selektive katalytische Epoxidierung
EP2065054A1 (en) 2007-11-29 2009-06-03 Bayer Schering Pharma Aktiengesellschaft Combinations comprising a prostaglandin and uses thereof
DE102007059752A1 (de) 2007-12-10 2009-06-18 Bayer Schering Pharma Aktiengesellschaft Funktionalisierte, feste Polymernanopartikel enthaltend Epothilone
EP2070521A1 (en) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Surface-modified nanoparticles
EP2210584A1 (en) 2009-01-27 2010-07-28 Bayer Schering Pharma Aktiengesellschaft Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer
EP2571525A4 (en) 2010-05-18 2016-04-27 Cerulean Pharma Inc Compositions and methods for treating autoimmune and other diseases
CA2858806A1 (en) 2011-12-23 2013-06-27 Innate Pharma Enzymatic conjugation of polypeptides
US10132799B2 (en) 2012-07-13 2018-11-20 Innate Pharma Screening of conjugated antibodies
EP2916872B1 (en) 2012-11-09 2019-02-27 Innate Pharma Recognition tags for tgase-mediated conjugation
US10611824B2 (en) 2013-03-15 2020-04-07 Innate Pharma Solid phase TGase-mediated conjugation of antibodies
US10071169B2 (en) 2013-06-20 2018-09-11 Innate Pharma Enzymatic conjugation of polypeptides
CN105517577A (zh) 2013-06-21 2016-04-20 先天制药公司 多肽的酶促偶联
WO2019092148A1 (en) 2017-11-10 2019-05-16 Innate Pharma Antibodies with functionalized glutamine residues

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54115320A (en) * 1978-02-28 1979-09-07 Soda Aromatic Novel unsaturated keto acid and its manufacture
JP2653663B2 (ja) * 1988-02-15 1997-09-17 財団法人微生物化学研究会 １．３―ジヒドロキシ―８―デセン―５―オンを含む免疫賦活剤及び制癌剤
EP0469480A3 (en) * 1990-08-01 1993-03-10 Hoechst Aktiengesellschaft Process for stereoselective preparation of 5-substituted delta-lactones and their use
WO1998038192A1 (de) * 1997-02-25 1998-09-03 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Seitenkettenmodifizierte epothilone
AU9340998A (en) * 1997-08-09 1999-03-01 Schering Aktiengesellschaft New epothilone derivatives, method for producing same and their pharmaceutical use

Also Published As

Publication number Publication date
KR20020005737A (ko) 2002-01-17
CZ299653B6 (cs) 2008-10-08
CZ20013885A3 (cs) 2002-04-17
HUP0201010A3 (en) 2005-02-28
ATE440847T1 (de) 2009-09-15
CN1349534A (zh) 2002-05-15
IL145938A0 (en) 2002-07-25
DK1173441T3 (da) 2009-12-07
DE60042821D1 (de) 2009-10-08
HRP20010892A2 (en) 2008-06-30
PL210762B1 (pl) 2012-02-29
ES2331506T3 (es) 2010-01-07
NZ514989A (en) 2004-02-27
SI1173441T1 (sl) 2010-01-29
SK15512001A3 (sk) 2002-05-09
CA2371226A1 (en) 2000-11-09
TW200711679A (en) 2007-04-01
CA2371226C (en) 2011-11-29
EE05292B1 (et) 2010-04-15
TWI294292B (en) 2008-03-11
HUP0201010A2 (en) 2002-08-28
NO328149B1 (no) 2009-12-21
EA011502B1 (ru) 2009-04-28
PE20010116A1 (es) 2001-02-15
HK1046681A1 (en) 2003-01-24
CY1109768T1 (el) 2014-09-10
MXPA01011039A (es) 2003-06-30
ZA200109859B (en) 2003-02-28
JP2007224038A (ja) 2007-09-06
CA2651653C (en) 2012-02-14
BG106053A (en) 2002-05-31
CN100368415C (zh) 2008-02-13
KR100721488B1 (ko) 2007-05-23
JP4024003B2 (ja) 2007-12-19
AR023792A1 (es) 2002-09-04
RS51023B (sr) 2010-10-31
NO20015278L (no) 2001-12-21
NO20015278D0 (no) 2001-10-29
WO2000066589A1 (en) 2000-11-09
JP2002543203A (ja) 2002-12-17
EA200101025A1 (ru) 2002-06-27
PL351491A1 (en) 2003-04-22
SK286858B6 (sk) 2009-06-05
CA2651653A1 (en) 2000-11-09
EP1173441B1 (en) 2009-08-26
JP4886578B2 (ja) 2012-02-29
TWI280962B (en) 2007-05-11
EP1173441A1 (en) 2002-01-23
BG65601B1 (bg) 2009-02-27
YU77601A (sh) 2005-07-19
PT1173441E (pt) 2009-11-06
HK1046681B (zh) 2008-08-29
BR0010190A (pt) 2002-01-08
EE200100568A (et) 2003-02-17

Similar Documents

Publication Publication Date Title
MEP13908A (en) 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations
CY1113654T1 (el) Αρυλ ουριες ως αναστολεις κινασων
Ayati et al. Synthesis and biological evaluation of 4-amino-5-cinnamoylthiazoles as chalcone-like anticancer agents
PL309392A1 (en) 7-halide and 7beta, 8beta-methane taxoles, their antineoplastic application and pharmaceutical compositions containing them
Malebari et al. β-Lactam analogues of combretastatin A-4 prevent metabolic inactivation by glucuronidation in chemoresistant HT-29 colon cancer cells
WO2007044729A3 (en) N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
HUP9802422A2 (hu) Szubsztituált izokinolin-3-karbonsavamid-származékok, eljárás előállításukra és ezeket a vegyületeket tartalmazó gyógyszerkészítmények
NO990066D0 (no) Apoptose-induserende adamantylderivater og deres anvendelse som anticancer-midler
CN101720315B (zh) PsammaplinA的衍生物、其合成方法以及其用于预防或治疗癌症的用途
DK0767786T3 (da) 7-ether-taxol-analoge, antineoplastisk anvendelse deraf og farmaceutiske præparater indeholdende disse forbindelser
HUP0102512A2 (hu) Áthidalt indeno-pirrolo-karbazol-származékok, eljárás az előállításukra, a vegyületeket tartalmazó gyógyászati készítmények és alkalmazásuk
WO2001081342A3 (de) Neue epothilon-derivate, verfahren zu deren herstellung und ihre pharmazeutische verwendung
Yong et al. Synthesis of isoxazole moiety containing ferrocene derivatives and preliminarily in vitro anticancer activity
Romu et al. Design, synthesis and biological evaluation of WZ4002 analogues as EGFR inhibitors
WO2000049020A3 (de) Neue epothilon-derivate, verfahren zu deren herstellung und ihre pharmazeutische verwendung
BR9910419A (pt) Etm-305, etm-204, etm-775, substancialmente puros, processos para tratar leucemia de mamìferos, para tratar carcinoma de pulmão de mamìferos, para tratar adenocarcinoma de cólon de mamìferos, e para tratar melanoma maligno de mamìferos, composição farmacêutica, e, processo para testar o metabolismo citocromo humano cyp3a4 de ecteinascidina 743
DE602004023271D1 (de) Metastin derivate und ihre verwendung
Li et al. Discovery of quinazoline derivatives as a novel class of potent and in vivo efficacious LSD1 inhibitors by drug repurposing
Asong et al. New analogs of SYA013 as sigma-2 ligands with anticancer activity
Bai et al. Novel hybrids of podophyllotoxin and coumarin inhibit the growth and migration of human oral squamous carcinoma cells
AR063417A1 (es) Compuestos inhibidores del activador de plasminogeno tipo 1(pai-1)
HUP9800649A2 (hu) Benzil-oxi-csoporttal helyettesített, kondenzált N-heterociklusos vegyületek, eljárás előállításukra és alkalmazásuk bradikinin receptorantagonistaként
ATE421324T1 (de) Verwendung von isochinolin-derivaten zur behandlung von krebs und erkrankungen im zusammenhang mit map kinase
MX2021012221A (es) Inhibidor del cd73, metodo de preparacion y aplicacion del mismo.
WO2012009663A3 (en) New compounds for treating cancer and other diseases